Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Conditions: Hepatocellular Carcinoma Interventions: Combination Product: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib Sponsors: Yongyi Zeng Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials